Lucheng Zhu

No.34, Yanguan Road
Hangzhou, 310002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Correction to: Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients.

Correction to: Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: June 10, 2026

Synergistic efficacy of radiotherapy and immunotherapy enhances clinical outcomes in patients with advanced non-small cell lung cancer.

Synergistic efficacy of radiotherapy and immunotherapy enhances clinical outcomes in patients with advanced non-small cell lung cancer.

Journal: Discover oncology

Published: December 15, 2025

Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer.

Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer.

Journal: Cancer letters

Published: September 07, 2025

Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients.

Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: June 27, 2025

Hyperthermia correlates with low incidence of radiation pneumonitis after thoracic radiotherapy: a retrospective study.

Hyperthermia correlates with low incidence of radiation pneumonitis after thoracic radiotherapy: a retrospective study.

Journal: BMC cancer

Published: May 31, 2025

Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study.

Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 12, 2025

Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022) 268-283].

Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022) 268-283].

Journal: Cancer letters

Published: November 24, 2024

Efficacy analysis of brain radiotherapy in EGFR mutation non-small cell lung cancer with brain metastasis: a retrospective study.

Efficacy analysis of brain radiotherapy in EGFR mutation non-small cell lung cancer with brain metastasis: a retrospective study.

Journal: Discover oncology

Published: November 22, 2024

The role of PD-L1 in EGFR-mutant non-small cell lung cancer.

The role of PD-L1 in EGFR-mutant non-small cell lung cancer.

Journal: Discover oncology

Published: September 20, 2024

Role of TLR7 expression in cancer: impact on immune activation and prognostic evaluation.

Role of TLR7 expression in cancer: impact on immune activation and prognostic evaluation.

Journal: Journal of translational medicine

Published: July 07, 2024

Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation.

Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation.

Journal: Discover oncology

Published: June 18, 2024

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity.

Hypofractionated stereotactic radiotherapy for brain metastases in lung cancer patients: dose‒response effect and toxicity.

Journal: Discover oncology

Published: March 22, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026